Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / pleiotrophin

pleiotrophin

Basics

Aliases:
This biomarker is also known as:
  • Heparin-binding growth-associated molecule,
  • HBBM,
  • HBNF1,
  • Heparin-binding growth factor 8,
  • neurite growth-promoting factor 1,
  • OSF-1,
  • heparin-binding brain mitogen,
  • HBNF-1,
  • heparin-binding growth-associated molecule,
  • NEGF1,
  • Heparin-binding brain mitogen,
  • HB-GAM,
  • heparin affin regulatory protein,
  • Osteoblast-specific factor 1,
  • HBGF8,
  • HBNF,
  • osteoblast-specific factor 1,
  • PTN,
  • heparin-binding growth factor 8,
  • heparin-binding neurite outgrowth-promoting factor 1,
  • Heparin-binding neurite outgrowth-promoting factor 1,
  • heparin binding growth factor 8,
  • HBGF-8,
  • pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1),
  • HARP,

View in BioMuta

Description…

Pleiotrophin, or PTN, is a secreted growth factor found in osteoblasts and brain tissue. PTN induces neurite outgrowth and is mitogenic for fibroblasts, epithelial, and endothelial cells. It binds anaplastic lymphoma kinase (ALK) which induces MAPK pathway activation, an important step in the anti-apoptotic signaling of PTN and regulation of cell proliferation.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

Pleiotrophin has been identified in serum and lung cancer tissue or cell culture as a candidate lung cancer biomarker. Pleiotrophin was also observed up-regulated in lung cancer in this study. Others studies have suggested that pleiotrophin may be an early indicator of lung cancer and might be of use in monitoring the efficacy of therapy.

Performance Comment

PTN, also known as pleiotrophin, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html